Abstract
Background and Aims: Factor Xa (FXa) and thrombin exert non-haemostatic cellular effects. Late-outgrowth endothelial cells (OECs) are a type of endothelial progenitor cells. We investigated the effect of rivaroxaban, a direct oral anticoagulant which specifically inhibits FXa’s activity, on FXa-and thrombin-induced OEC activation, using as activation markers the ICAM-1 membrane expression and MCP-1 secretion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
